New Zealand markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.06+0.25 (+1.80%)
As of 03:17PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 386.27M
Enterprise value 716.30M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.09
Price/book (mrq)44.19
Enterprise value/revenue 1.93
Enterprise value/EBITDA -36.40

Trading information

Stock price history

Beta (5Y monthly) 1.26
52-week change 3-30.92%
S&P500 52-week change 3-13.03%
52-week high 320.50
52-week low 310.81
50-day moving average 315.71
200-day moving average 316.15

Share statistics

Avg vol (3-month) 3958.71k
Avg vol (10-day) 3648.54k
Shares outstanding 529.71M
Implied shares outstanding 6N/A
Float 824.57M
% held by insiders 14.50%
% held by institutions 197.12%
Shares short (14 Jun 2022) 49.76M
Short ratio (14 Jun 2022) 413.11
Short % of float (14 Jun 2022) 446.45%
Short % of shares outstanding (14 Jun 2022) 432.85%
Shares short (prior month 12 May 2022) 48.74M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -18.44%
Operating margin (ttm)-9.95%

Management effectiveness

Return on assets (ttm)-4.50%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)370.39M
Revenue per share (ttm)11.94
Quarterly revenue growth (yoy)8.50%
Gross profit (ttm)360.37M
EBITDA -34.36M
Net income avi to common (ttm)-68.29M
Diluted EPS (ttm)-2.20
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)395.7M
Total cash per share (mrq)13.32
Total debt (mrq)725.73M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.16
Book value per share (mrq)-12.51

Cash flow statement

Operating cash flow (ttm)-7.11M
Levered free cash flow (ttm)13.02M